Page last updated: 2024-10-15

cobrotoxin

Description

Cobra Neurotoxin Proteins: Toxins, contained in cobra (Naja) venom that block cholinergic receptors; two specific proteins have been described, the small (short, Type I) and the large (long, Type II) which also exist in other Elapid venoms. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16132280
MeSH IDM0004667

Synonyms (8)

Synonym
m9rl1jf99o ,
cobrotoxin
12584-83-7
cobra neurotoxin proteins
unii-m9rl1jf99o
11103-42-7
cobrotoxin (reduced)
alpha-cobratoxin from naja atra

Research Excerpts

Overview

Cobrotoxin (CBTX) is a highly toxic short neurotoxin. isolated from the Taiwan cobra (Naja naja atra) venom.

ExcerptReference
"Cobrotoxin (CBTX) is a highly toxic short neurotoxin, isolated from the Taiwan cobra (Naja naja atra) venom. "( Cloning, overexpression, and characterization of cobrotoxin.
Hsieh, HC; Kumar, TK; Yu, C, 2004
)

Actions

ExcerptReference
"Cobrotoxin can suppress the growth of A549 in vitro. "( [Role of autophagy on cobrotoxin induced cell death of A549].
Han, R; He, J; Li, R; Shen, J; Tang, X; Wu, Y; Xu, C, 2013
)

Pharmacokinetics

ExcerptReference
"The purpose of this study was to encapsulate NT within polylactic acid (PLA) nanoparticles (NPs) modified with chitosan (NT-PLA-cNPs) and to evaluate their brain pharmacokinetic behaviors after intranasal (i."( Brain pharmacokinetics of neurotoxin-loaded PLA nanoparticles modified with chitosan after intranasal administration in awake rats.
Chai, G; Li, F; Liu, L; Zhang, X, 2013
)
" To date, however, pharmacokinetic reports on cobra venoms and their toxins are still relatively limited."( Pharmacokinetics of Naja sumatrana (equatorial spitting cobra) venom and its major toxins in experimentally envenomed rabbits.
Fung, SY; Sim, SM; Tan, CH; Tan, NH; Yap, MK, 2014
)
"3 ml/h), terminal phase half-life (13."( Pharmacokinetics of Naja sumatrana (equatorial spitting cobra) venom and its major toxins in experimentally envenomed rabbits.
Fung, SY; Sim, SM; Tan, CH; Tan, NH; Yap, MK, 2014
)

Bioavailability

ExcerptReference
" The corresponding absolute bioavailability (Fabs) of NT-PLA-cNPs was about 151% with NT-PLA-NPs as reference preparations."( Brain pharmacokinetics of neurotoxin-loaded PLA nanoparticles modified with chitosan after intranasal administration in awake rats.
Chai, G; Li, F; Liu, L; Zhang, X, 2013
)
"6 h) and systemic bioavailability (41."( Pharmacokinetics of Naja sumatrana (equatorial spitting cobra) venom and its major toxins in experimentally envenomed rabbits.
Fung, SY; Sim, SM; Tan, CH; Tan, NH; Yap, MK, 2014
)
"Our results suggest that the venom neurotoxin is absorbed very rapidly and has the highest bioavailability following intramuscular injection, supporting its role as the principal toxin in systemic envenoming."( Pharmacokinetics of Naja sumatrana (equatorial spitting cobra) venom and its major toxins in experimentally envenomed rabbits.
Fung, SY; Sim, SM; Tan, CH; Tan, NH; Yap, MK, 2014
)

Dosage Studied

ExcerptReference
" While dose adjustment according to geographical region seems possible, changes to standard recommended dosage should only be made if further study validates that the monocled cobras within a population do not exhibit remarkable inter-individual venom variation."( Venomics, lethality and neutralization of Naja kaouthia (monocled cobra) venoms from three different geographical regions of Southeast Asia.
Fung, SY; Tan, CH; Tan, KY; Tan, NH, 2015
)
" This is consistent with the high abundance of neurotoxins in the NK-T venom, implying that a larger amount or repeated dosing of NKMAV may be required in NK-T envenomation."( Geographical venom variations of the Southeast Asian monocled cobra (Naja kaouthia): venom-induced neuromuscular depression and antivenom neutralization.
Fung, SY; Sim, SM; Tan, CH; Tan, KY; Tan, NH,
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (394)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990134 (34.01)18.7374
1990's129 (32.74)18.2507
2000's78 (19.80)29.6817
2010's39 (9.90)24.3611
2020's14 (3.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (0.97%)5.53%
Reviews15 (3.64%)6.00%
Case Studies3 (0.73%)4.05%
Observational0 (0.00%)0.25%
Other390 (94.66%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]